A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer (PFE) currently faces dual concerns in the market about its growth prospects and dividend safety, causing its valuation to remain low. However, from the perspective of financial ...

Key TakeawaysVaxcyte’s VAX-31 matched Pfizer’s Prevnar 20 on all 20 shared serotypes and Merck’s Capvaxive on 17 of 19 in a 4,047-person Phase 3 trial. Prevnar brought in $6.

“Do not impact fertility.” That was the headline assurance in a February 2021 joint statement⁠ from the American College of ...

Vaxcyte shares surged after its experimental VAX-31 pneumococcal vaccine met the main goals of a late-stage trial, though regulatory approval and commercial manufacturing remain years away.

Pfizer is a stock that looks well overdue for a rally. Although it's been rising this year, it can still have much more to ...

Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ...